AU2020271915B2 - Compounds and methods for treating inflammatory disorders - Google Patents

Compounds and methods for treating inflammatory disorders

Info

Publication number
AU2020271915B2
AU2020271915B2 AU2020271915A AU2020271915A AU2020271915B2 AU 2020271915 B2 AU2020271915 B2 AU 2020271915B2 AU 2020271915 A AU2020271915 A AU 2020271915A AU 2020271915 A AU2020271915 A AU 2020271915A AU 2020271915 B2 AU2020271915 B2 AU 2020271915B2
Authority
AU
Australia
Prior art keywords
compound
doi
och
pharmaceutically acceptable
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020271915A
Other languages
English (en)
Other versions
AU2020271915A1 (en
Inventor
Gerald BILLAC
Charles D. Nichols
David E. Nichols
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
Original Assignee
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University filed Critical Louisiana State University
Publication of AU2020271915A1 publication Critical patent/AU2020271915A1/en
Application granted granted Critical
Publication of AU2020271915B2 publication Critical patent/AU2020271915B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2020271915A 2019-04-12 2020-04-13 Compounds and methods for treating inflammatory disorders Active AU2020271915B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962833140P 2019-04-12 2019-04-12
US62/833,140 2019-04-12
PCT/US2020/027981 WO2020210823A1 (en) 2019-04-12 2020-04-13 Compounds and methods for treating inflammatory disorders

Publications (2)

Publication Number Publication Date
AU2020271915A1 AU2020271915A1 (en) 2021-11-04
AU2020271915B2 true AU2020271915B2 (en) 2025-10-09

Family

ID=72751451

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020271915A Active AU2020271915B2 (en) 2019-04-12 2020-04-13 Compounds and methods for treating inflammatory disorders

Country Status (9)

Country Link
US (2) US12398093B2 (https=)
EP (2) EP3952851B1 (https=)
JP (1) JP7596296B2 (https=)
KR (1) KR20220008264A (https=)
CN (2) CN113784709B (https=)
AU (1) AU2020271915B2 (https=)
BR (1) BR112021020424A2 (https=)
CA (1) CA3136153A1 (https=)
WO (1) WO2020210823A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL309842A (en) * 2021-07-26 2024-02-01 Univ Louisiana State Compounds and methods for treating situations where the response depends on 5-HT2
SE2151519A1 (en) 2021-12-10 2023-06-11 Amidea Sweden Ab 2-(2,5-dimethoxyphenyl)ethanamine and uses thereof
WO2024010765A1 (en) * 2022-07-05 2024-01-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions for treating 5-ht2 conditions and methods of using the same
WO2024191924A2 (en) * 2023-03-10 2024-09-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180055791A1 (en) * 2008-07-10 2018-03-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Low dosage serotonin 5-ht2a receptor agonist to suppress inflammation
WO2018204354A1 (en) * 2017-05-01 2018-11-08 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to reduce pathogenesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016190A2 (en) * 2005-07-28 2007-02-08 Duke University Antiparkinsonian action of phenylisopropylamines
EP2884962B1 (en) * 2012-08-17 2019-05-01 Smartek International LLC Preparation of desiccated liposomes for use in compressible delivery systems
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180055791A1 (en) * 2008-07-10 2018-03-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Low dosage serotonin 5-ht2a receptor agonist to suppress inflammation
WO2018204354A1 (en) * 2017-05-01 2018-11-08 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to reduce pathogenesis

Also Published As

Publication number Publication date
CN113784709B (zh) 2024-05-10
US20220119340A1 (en) 2022-04-21
EP4685135A3 (en) 2026-04-15
EP4685135A2 (en) 2026-01-28
KR20220008264A (ko) 2022-01-20
BR112021020424A2 (pt) 2021-12-21
JP2022527401A (ja) 2022-06-01
WO2020210823A1 (en) 2020-10-15
JP7596296B2 (ja) 2024-12-09
EP3952851B1 (en) 2025-12-03
EP3952851A4 (en) 2023-01-11
CA3136153A1 (en) 2020-10-15
AU2020271915A1 (en) 2021-11-04
US12398093B2 (en) 2025-08-26
CN113784709A (zh) 2021-12-10
EP3952851A1 (en) 2022-02-16
US20260070872A1 (en) 2026-03-12
CN118384143A (zh) 2024-07-26

Similar Documents

Publication Publication Date Title
US20260070872A1 (en) Compounds and methods for treating inflammatory disorders
JP5196701B2 (ja) クロモリンナトリウムの経口投与用製剤
EP1807083B1 (en) Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
CN109820853B (zh) 取代的杂环化合物在制备治疗癌症药物中的用途
CN116650500B (zh) 治疗癌症的方法
KR20090129414A (ko) 인플루엔자 치료제
US11236044B2 (en) Selective inhibitors of 12(S)-lipoxygenase (12-LOX) and methods for use of the same
KR101633717B1 (ko) 벤조페난트리딘 구조를 갖는 항종양제 및 그를 함유하는 제제
JP2005512998A (ja) 抗マラリア治療剤に対する新規の使用
JP2023516284A (ja) カンナビジオールの組成物および治療的使用
JPH09507219A (ja) α−２−アドレノセプター作動剤として有用な７−（２−イミダゾリニルアミノ）キノリン化合物
JP2025511217A (ja) メセンブリンの塩形態
US10266490B2 (en) Radioprotector compounds
JP2008526948A (ja) 抗マラリア活性を有する９ａ−カルバモイルおよびチオカルバモイルアザライド
US20230339942A1 (en) Inhibitors of ubiquitin specific peptidase 22 (usp22) and uses thereof for treating diseases and disorders
HK40056643A (en) Compounds and methods for treating inflammatory disorders
AU2022239497A1 (en) Compositions and methods for treating neurologic diseases
KR20130130802A (ko) 보르트만닌 유사체의 결정질 형태의 조성물 및 이의 사용 방법
WO2005011674A1 (ja) 気管支喘息の予防及び／または治療剤
US6608080B1 (en) Morphan derivatives or salts thereof and medicinal compositions containing the same
US20250270205A1 (en) Compositions and methods for inhibiting trem-1
WO2024059853A2 (en) Haph analogs and therapeutic and diagnostic uses thereof
JPH04506517A (ja) ３，３―ジ置換インドリンの鼻腔内投与
HK40096678A (zh) 用於预防或治疗纤维化的药物组合物
JPWO2005056009A1 (ja) 肺疾患治療剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)